Clinical Trials · 2010 · 20 citations · 14 references
Public HealthPopulation Health SciencesPreventive MedicineCancer PreventionEpidemiologic MethodsHealth EquityClinical TrialsCommunity Cancer PreventionParticipant RecruitmentPopulation-based Cancer ControlStudy DesignSubgroup AnalysisClinical Trial Participation DisparitiesDisease Burden AnalysisMinority Candidate RecruitmentPost Hoc AnalysisPost Hoc Subgroup AnalysisPrevention TrialsRacial Cancer DisparitiesTrial Accrual
BACKGROUND: African American accrual to prevention trials at rates representative of the disease burden experienced by this population requires additional resources and focused efforts. PURPOSE: To describe the rationale, context, and criteria for selection of sites that received Minority Recruitment Enhancement Grants (MREGs) to increase African American recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). To determine if African American accrual was higher among the 15 MREG sites when compared with similar nonawarded sites. METHODS: Changes in African American accrual at sites that received MREGs are compared with changes in a group of 15, frequency-matched, nonawarded sites using a quasi-experimental, post hoc analysis. Successful and unsuccessful recruitment strategies reported by the MREG sites are described. RESULTS: The increased number of African American participants accrued per month at MREG sites post-funding was higher than the change at comparison sites by a factor of 3.38 (p = 0.004, 95% CI: 1.51-7.57). An estimated 602 additional African American participants were recruited at MREG sites due to MREG funding, contributing to the overall 14.9% African American recruitment. Successful recruitment strategies most reported by MREG sites included increasing staff, transportation resources, recruiting through the media, mailings, and prostate cancer screening clinics during off-hours. LIMITATIONS: Comparison sites were chosen retrospectively, not by randomization. Although comparison sites were selected to be similar to MREG sites with regard to potential confounding factors, it is possible that unknown factors could have biased results. Cost-effective analyses were not conducted. CONCLUSIONS: MREG sites increased African American accrual in the post-funding period more than comparison sites, indicating MREG funding enhanced the sites' abilities to accrue African American participants. Targeted grants early in the accrual period may be a useful multi-site intervention to increase African American accrual for a prevention study where adequate African American representation is essential.
14
Why African Americans may not be participating in clinical trials.
Yvonne Harris, Philip B. Gorelick, Philip Samuels et al. · PubMed · 1996 · 286 citations
Medicine, African American Studies, Clinical Trial Regulation +10
Philip B. Gorelick, Yvonne Harris, Bruce Burnett et al. · PubMed · 1998 · 196 citations
Design of the Prostate Cancer Prevention Trial (PCPT)
Polly Feigl, Brent A. Blumenstein, Ian M. Thompson et al. · Controlled Clinical Trials · 1995 · 132 citations